Cevimeline

Cevimeline
Clinical data
Trade names	Evoxac
AHFS/Drugs.com	Monograph
MedlinePlus	a608025
Pregnancy; category	C;
Routes of; administration	By mouth (capsules)
ATC code	N07AX03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	<20%
Identifiers
	IUPAC name (2R,2R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane];
CAS Number	107233-08-9 ;
PubChem CID	83898;
DrugBank	DB00185 ;
ChemSpider	75707 ;
UNII	K9V0CDQ56E;
KEGG	D07667 ;
ChEBI	CHEBI:3568 ;
ChEMBL	ChEMBL1201267 ;
CompTox Dashboard (EPA)	DTXSID801342027 DTXSID40274384, DTXSID801342027 ;
Chemical and physical data
Formula	C10H17NOS
Molar mass	199.31 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O1[C@H](SC[C@@]12CN3CCC2CC3)C;
	InChI InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m1/s1 ; Key:WUTYZMFRCNBCHQ-PSASIEDQSA-N ;
	(what is this?) (verify)

Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M₁ and M₃ receptors. It is used in the treatment of dry mouth and Sjögren's syndrome.